Drug intelligence / Profile preview

25ND01

Development stage: Preclinical
Lead developer: HK inno.N Corporation
Modality: Small Molecules
Administration: Oral, Nasogastric

Overview

25ND01 is an early-stage small molecule drug candidate being developed by HK inno.N for the treatment of obesity. Currently in the discovery phase, the specific biological target and mechanism of action for this compound have not yet been publicly disclosed. It is part of a broader portfolio of metabolic and inflammatory disease treatments under development by the South Korean pharmaceutical company. The program represents part of the company's long-term strategy to expand its presence in the metabolic disease market beyond its flagship gastrointestinal products.

Beyond the preview

Go deeper on 25ND01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 25ND01.

Explore the full profile